Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
1,590 questions in 129 reviews · Gynaecological, Neuro-oncology and Orphan Cancer
current versionsNo studies 281 · 17.7%Ungraded 74 · 4.7%Very low 410 · 25.8%Low 420 · 26.4%Moderate 280 · 17.6%High 125 · 7.9%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
EGFR tyrosine kinase inhibitor (TKI) vs observation alone Progression‐free survival · maintenance treatment of epithelial ovarian cancer after first‐line chemotherapy Epidermal growth factor receptor blockers for the treatment of ovarian cancer (2018) · Cochrane | HR 1.05 [0.9, 1.23] | 1 study · 835 participants | Very low |
Anti‐EGFR antibody plus chemotherapy vs chemotherapy alone Quality of life · treatment of relapsed epithelial ovarian cancer Epidermal growth factor receptor blockers for the treatment of ovarian cancer (2018) · Cochrane | no estimate extracted | NR | No studies |
EGFR tyrosine kinase inhibitor (TKI) vs observation alone Quality of life · maintenance treatment of epithelial ovarian cancer after first‐line chemotherapy Epidermal growth factor receptor blockers for the treatment of ovarian cancer (2018) · Cochrane | no estimate extracted | 1 study · 835 participants | Very low |
EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy vs chemotherapy alone Overall survival · treatment of relapsed epithelial ovarian cancer Epidermal growth factor receptor blockers for the treatment of ovarian cancer (2018) · Cochrane | HR 1.25 [0.8, 1.95] | 1 study · 129 participants | Low |
EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy vs chemotherapy alone Progression‐free survival · treatment of relapsed epithelial ovarian cancer Epidermal growth factor receptor blockers for the treatment of ovarian cancer (2018) · Cochrane | HR 0.99 [0.69, 1.42] | 1 study · 129 participants | Very low |
EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy vs chemotherapy alone Toxicity: grade 3 or 4 rash · treatment of relapsed epithelial ovarian cancer Epidermal growth factor receptor blockers for the treatment of ovarian cancer (2018) · Cochrane | RR 13.63 [0.78, 236.87] | 1 study · 125 participants | Very low |
EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy vs chemotherapy alone Toxicity: grade 3 or 4 nausea ± vomiting · treatment of relapsed epithelial ovarian cancer Epidermal growth factor receptor blockers for the treatment of ovarian cancer (2018) · Cochrane | RR 0.63 [0.16, 2.52] | 1 study · 125 participants | Very low |
EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy vs chemotherapy alone Toxicity: grade 3 or 4 fatigue · treatment of relapsed epithelial ovarian cancer Epidermal growth factor receptor blockers for the treatment of ovarian cancer (2018) · Cochrane | RR 0.87 [0.28, 2.72] | 1 study · 125 participants | Very low |
EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy vs chemotherapy alone Toxicity: cardiac toxicity (any grade) · treatment of relapsed epithelial ovarian cancer Epidermal growth factor receptor blockers for the treatment of ovarian cancer (2018) · Cochrane | RR 5.24 [0.26, 107.02] | 1 study · 125 participants | Low |
Anti‐angiogenic therapy vs no anti‐angiogenic therapy Overall survival ( · people with HGG Anti‐angiogenic therapy for high‐grade glioma (2018) · Cochrane | HR 0.95 [0.88, 1.02] | 11 studies · 3743 participants | High |
Anti‐angiogenic therapy vs no anti‐angiogenic therapy Progression‐free survival ( · people with HGG Anti‐angiogenic therapy for high‐grade glioma (2018) · Cochrane | HR 0.73 [0.68, 0.79] | 10 studies · 3595 participants | High |
Anti‐angiogenic therapy vs no anti‐angiogenic therapy Overall survival ( · people with HGG Anti‐angiogenic therapy for high‐grade glioma (2018) · Cochrane | HR 0.93 [0.86, 1.02] | 8 studies · 2833 participants | High |
Anti‐angiogenic therapy vs no anti‐angiogenic therapy Overall survival ( · people with HGG Anti‐angiogenic therapy for high‐grade glioma (2018) · Cochrane | HR 0.99 [0.85, 1.16] | 3 studies · 910 participants | Moderate |
Anti‐angiogenic therapy vs no anti‐angiogenic therapy Overall survival ( · people with HGG Anti‐angiogenic therapy for high‐grade glioma (2018) · Cochrane | HR 0.92 [0.85, 1] | 11 studies · 3506 participants | Low |
Anti‐angiogenic therapy vs no anti‐angiogenic therapy Progression‐free survival ( · people with HGG Anti‐angiogenic therapy for high‐grade glioma (2018) · Cochrane | HR 0.75 [0.69, 0.82] | 8 studies · 2833 participants | High |
Anti‐angiogenic therapy vs no anti‐angiogenic therapy Progression‐free survival ( · people with HGG Anti‐angiogenic therapy for high‐grade glioma (2018) · Cochrane | HR 0.64 [0.54, 0.76] | 2 studies · 762 participants | Moderate |
Anti‐angiogenic therapy vs no anti‐angiogenic therapy Progression‐free survival ( · people with HGG Anti‐angiogenic therapy for high‐grade glioma (2018) · Cochrane | HR 0.72 [0.66, 0.77] | 10 studies · 3464 participants | High |
Oestrogen replacement therapy vs placebo Rate of symptom relief · women previously treated for endometrial cancer Hormone replacement therapy for women previously treated for endometrial cancer (2018) · Cochrane | no estimate extracted | NR | No studies |
Oestrogen replacement therapy vs placebo Rate of tumour recurrence · women previously treated for endometrial cancer Hormone replacement therapy for women previously treated for endometrial cancer (2018) · Cochrane | RR 1.17 [0.54, 2.5] | 1 study · 1236 participants | Very low |
Oestrogen replacement therapy vs placebo Rate of appearance of a new malignancy · women previously treated for endometrial cancer Hormone replacement therapy for women previously treated for endometrial cancer (2018) · Cochrane | RR 0.8 [0.32, 2.01] | 1 study · 1236 participants | Very low |
Oestrogen replacement therapy vs placebo Rate of survival: overall survival · women previously treated for endometrial cancer Hormone replacement therapy for women previously treated for endometrial cancer (2018) · Cochrane | no estimate extracted | NR | No studies |
Oestrogen replacement therapy vs placebo Rate of survival: progression‐free survival · women previously treated for endometrial cancer Hormone replacement therapy for women previously treated for endometrial cancer (2018) · Cochrane | no estimate extracted | NR | No studies |
Probiotics vs placebo Any diarrhoea · participants with cancer treated with radiotherapy (with or without chemotherapy) Probiotics for the prevention or treatment of chemotherapy‐ or radiotherapy‐related diarrhoea in people with… (2018) · Cochrane | no estimate extracted | 3 studies · 771 participants | Low |
Probiotics vs placebo Any diarrhoea · participants with cancer treated with chemotherapy Probiotics for the prevention or treatment of chemotherapy‐ or radiotherapy‐related diarrhoea in people with… (2018) · Cochrane | RR 0.59 [0.36, 0.96] | 2 studies · 106 participants | Low |
Probiotics vs placebo Quality of life ‐ not measured · participants with cancer treated with chemotherapy Probiotics for the prevention or treatment of chemotherapy‐ or radiotherapy‐related diarrhoea in people with… (2018) · Cochrane | no estimate extracted | NR | No studies |
Probiotics vs placebo Diarrhoea grade 2 or higher · participants with cancer treated with chemotherapy Probiotics for the prevention or treatment of chemotherapy‐ or radiotherapy‐related diarrhoea in people with… (2018) · Cochrane | RR 0.67 [0.22, 2.05] | 1 study · 46 participants | Low |
Probiotics vs placebo Diarrhoea grade 3 or higher · participants with cancer treated with chemotherapy Probiotics for the prevention or treatment of chemotherapy‐ or radiotherapy‐related diarrhoea in people with… (2018) · Cochrane | RR 0.11 [0.01, 1.95] | 1 study · 46 participants | Low |
Probiotics vs placebo Diarrhoea grade 4 · participants with cancer treated with chemotherapy Probiotics for the prevention or treatment of chemotherapy‐ or radiotherapy‐related diarrhoea in people with… (2018) · Cochrane | RR 0.33 [0.01, 7.78] | 1 study · 46 participants | Low |
Probiotics vs placebo Time to rescue medication ‐ not measured · participants with cancer treated with chemotherapy Probiotics for the prevention or treatment of chemotherapy‐ or radiotherapy‐related diarrhoea in people with… (2018) · Cochrane | no estimate extracted | NR | No studies |
Probiotics vs placebo Requiring rescue medication for diarrhoea · participants with cancer treated with chemotherapy Probiotics for the prevention or treatment of chemotherapy‐ or radiotherapy‐related diarrhoea in people with… (2018) · Cochrane | no estimate extracted | 1 study · 46 participants | Low |
Probiotics vs placebo Adverse events · participants with cancer treated with chemotherapy Probiotics for the prevention or treatment of chemotherapy‐ or radiotherapy‐related diarrhoea in people with… (2018) · Cochrane | no estimate extracted | 2 studies · 106 participants | Low |
Probiotics vs placebo Mortality · participants with cancer treated with chemotherapy Probiotics for the prevention or treatment of chemotherapy‐ or radiotherapy‐related diarrhoea in people with… (2018) · Cochrane | no estimate extracted | 3 studies · 128 participants | Low |
Probiotics vs other active treatment Any diarrhoea · participants with cancer treated with radiotherapy (with or without chemotherapy) Probiotics for the prevention or treatment of chemotherapy‐ or radiotherapy‐related diarrhoea in people with… (2018) · Cochrane | RR 0.3 [0.11, 0.81] | 1 study · 21 participants | Very low |
Probiotics vs placebo Quality of life · participants with cancer treated with radiotherapy (with or without chemotherapy) Probiotics for the prevention or treatment of chemotherapy‐ or radiotherapy‐related diarrhoea in people with… (2018) · Cochrane | no estimate extracted | 1 study · 72 participants | Low |
Probiotics vs other active treatment Quality of life ‐ not measured · participants with cancer treated with radiotherapy (with or without chemotherapy) Probiotics for the prevention or treatment of chemotherapy‐ or radiotherapy‐related diarrhoea in people with… (2018) · Cochrane | no estimate extracted | NR | No studies |
Probiotics vs other active treatment Severity of diarrhoea: grade 3 or higher · participants with cancer treated with radiotherapy (with or without chemotherapy) Probiotics for the prevention or treatment of chemotherapy‐ or radiotherapy‐related diarrhoea in people with… (2018) · Cochrane | OR 0.38 [0.16, 0.89] | 1 study · 148 participants | Low |
Probiotics vs other active treatment Time to rescue medication ‐ not measured · participants with cancer treated with radiotherapy (with or without chemotherapy) Probiotics for the prevention or treatment of chemotherapy‐ or radiotherapy‐related diarrhoea in people with… (2018) · Cochrane | no estimate extracted | NR | No studies |
Probiotics vs other active treatment Requiring rescue medication for diarrhoea · participants with cancer treated with radiotherapy (with or without chemotherapy) Probiotics for the prevention or treatment of chemotherapy‐ or radiotherapy‐related diarrhoea in people with… (2018) · Cochrane | RR 0.44 [0.22, 0.86] | 2 studies · 63 participants | Very low |
Probiotics vs other active treatment Adverse events · participants with cancer treated with radiotherapy (with or without chemotherapy) Probiotics for the prevention or treatment of chemotherapy‐ or radiotherapy‐related diarrhoea in people with… (2018) · Cochrane | no estimate extracted | 3 studies · 211 participants | Very low |
Probiotics vs other active treatment Mortality · participants with cancer treated with radiotherapy (with or without chemotherapy) Probiotics for the prevention or treatment of chemotherapy‐ or radiotherapy‐related diarrhoea in people with… (2018) · Cochrane | no estimate extracted | 3 studies · 211 participants | Low |
Probiotics vs placebo Reduction in severity of diarrhoea · participants with cancer treated with radiotherapy (with or without chemotherapy) Probiotics for the prevention or treatment of chemotherapy‐ or radiotherapy‐related diarrhoea in people with… (2018) · Cochrane | no estimate extracted | 1 study · 205 participants | Moderate |
Probiotics vs placebo Quality of life ‐ not measured · participants with cancer treated with radiotherapy (with or without chemotherapy) Probiotics for the prevention or treatment of chemotherapy‐ or radiotherapy‐related diarrhoea in people with… (2018) · Cochrane | no estimate extracted | NR | No studies |
Probiotics vs placebo Time to rescue medication (in hours) · participants with cancer treated with radiotherapy (with or without chemotherapy) Probiotics for the prevention or treatment of chemotherapy‐ or radiotherapy‐related diarrhoea in people with… (2018) · Cochrane | no estimate extracted | 1 study · 205 participants | Moderate |
Probiotics vs placebo Requiring rescue medication for diarrhoea · participants with cancer treated with radiotherapy (with or without chemotherapy) Probiotics for the prevention or treatment of chemotherapy‐ or radiotherapy‐related diarrhoea in people with… (2018) · Cochrane | RR 0.74 [0.53, 1.03] | 1 study · 205 participants | Moderate |
Probiotics vs placebo Diarrhoea grade 2 or higher · participants with cancer treated with radiotherapy (with or without chemotherapy) Probiotics for the prevention or treatment of chemotherapy‐ or radiotherapy‐related diarrhoea in people with… (2018) · Cochrane | RR 0.75 [0.55, 1.03] | 4 studies · 420 participants | Low |
Probiotics vs placebo Adverse events · participants with cancer treated with radiotherapy (with or without chemotherapy) Probiotics for the prevention or treatment of chemotherapy‐ or radiotherapy‐related diarrhoea in people with… (2018) · Cochrane | no estimate extracted | 1 study · 205 participants | Moderate |
Probiotics vs placebo Mortality · participants with cancer treated with radiotherapy (with or without chemotherapy) Probiotics for the prevention or treatment of chemotherapy‐ or radiotherapy‐related diarrhoea in people with… (2018) · Cochrane | no estimate extracted | 1 study · 205 participants | Moderate |
Probiotics vs placebo Diarrhoea grade 3 or higher · participants with cancer treated with radiotherapy (with or without chemotherapy) Probiotics for the prevention or treatment of chemotherapy‐ or radiotherapy‐related diarrhoea in people with… (2018) · Cochrane | no estimate extracted | 3 studies · 793 participants | Low |
Probiotics vs placebo Diarrhoea grade 4 · participants with cancer treated with radiotherapy (with or without chemotherapy) Probiotics for the prevention or treatment of chemotherapy‐ or radiotherapy‐related diarrhoea in people with… (2018) · Cochrane | no estimate extracted | 1 study · 226 participants | Very low |
Probiotics vs placebo Time to rescue medication · participants with cancer treated with radiotherapy (with or without chemotherapy) Probiotics for the prevention or treatment of chemotherapy‐ or radiotherapy‐related diarrhoea in people with… (2018) · Cochrane | no estimate extracted | 1 study · 482 participants | Moderate |